Researcher Resources

Concentrating On The Cure

Who We Work With


Corrie Painter, PhD

Deputy Director, Count Me In

Broad Institute of MIT and Harvard

Working with the OSI has been one of the greatest honors of my professional career. As a sarcoma patient and as a cancer research scientist, I am committed to developing a comprehensive resource for the osteosarcoma community in order to drive discoveries and save lives. The sense of urgency that drives me is matched by everyone I’ve worked with at the OSI and I have faith that we will transform our understanding of this devastating disease.

What We Fund


Clinical Trials

A clinical study with osteosarcoma patients is the culmination and ultimate test for often years of translational science work. We prioritze novel approaches that have strong preclinical rationales, and utilize an innovative trial model that allows a rapid readout of effectiveness.


Correlative Studies

Clinical trials are focused on determining whether an experimental therapy works so they usually do not include funding to study why the treatment does or does not work. Such correlative studies can add a valuable additional level of understanding to inform future development.


Translational Studies

Osteosarcoma is a complex, poorly understood cancer. We seek out projects that will generate seminal preclinical bilogicial insights and suggest new ways to attack the disease.

The Grant Process

The OSI funds grants in three osteosarcoma research areas:


Clinical trials of new potential therapies that have promising preclinical rationales


Correlative science – the evaluation of how and why a potential new therapy works, or doesn’t work, in clinical trials


The basic biology of osteosarcoma and its metastasis, looking for clues for how to attack it

Our principal grant mechanism involves an annual, two-stage process. In early fall, we issue a call for summary, letter of intent proposals in the three areas above.  In late fall, we convene expert review committees to evaluate these summary proposals and select finalists, who are invited to submit full, detailed proposals. The full proposals are evaluated, and grants are awarded in late spring.

Because some projects may not fit in this timeline, we have a separate, ad-hoc procedure to consider “out-of-cycle” grants using the same criteria and standards. 

To inquire about “out-of-cycle” grant funding, please email


OSI board members include physicians and basic science researchers who are continually introduced to innovative ideas and technologies at medical meetings and research conferences, or within the halls of their own institutions.  If an intriguing idea is far enough along, its champion can be encouraged to apply for one of the main OSI grants.  But often times such an idea is in a nascent stage and needs a relatively small but timely investment to establish its feasibility for further development in osteosarcoma.  The OSI has established a discretionary grant program to pursue these opportunities.  On the spot grants of up to $20,000 can be nimbly authorized by committees of OSI board members. To inquire about discretionary grants, please email

Past RFPs

Our annual grant application window closed on November 15, 2020. Please see below for past RFPs and for information on out-of-cycle grants.

Off Cycle Requests

Our annual grant application window closed on November 15, 2020. While our annual process constitutes the primary OSI grantmaking mechanism, we recognize that not all projects are compatible with that time frame; accordingly, we consider out-of-cycle proposals on a case-by-case basis. Contact us for information on making an out-of-cycle proposal.

Before You Go

Sign-up for our newsletter and stay up-to-date about our fight against Osteosarcoma!

Translate »